alendronate has been researched along with Deficiency, Vitamin D in 24 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether secondary hyperparathyroidism (HPTH) due to hypovitaminosis D affects bone mineral density (BMD) response to alendronate (ALN) in elderly women with osteoporosis." | 9.12 | Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. ( Barone, A; Bianchi, G; Girasole, G; Giusti, A; Palummeri, E; Pioli, G; Pizzonia, M; Razzano, M, 2007) |
| " The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD." | 5.12 | Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. ( Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K, 2006) |
| "To determine whether secondary hyperparathyroidism (HPTH) due to hypovitaminosis D affects bone mineral density (BMD) response to alendronate (ALN) in elderly women with osteoporosis." | 5.12 | Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. ( Barone, A; Bianchi, G; Girasole, G; Giusti, A; Palummeri, E; Pioli, G; Pizzonia, M; Razzano, M, 2007) |
| "Patients were eligible for inclusion if they had osteoporosis or osteopenia and demonstrated a decline in BMD during the preceding year while taking stable doses of alendronate or risedronate, plus supplemental calcium and vitamin D." | 3.74 | Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. ( Adams, JS; Geller, JL; Hu, B; Mirocha, J; Reed, S, 2008) |
| "Osteoporosis is a common but neglected problem in India." | 2.42 | Management of osteoporosis: the Indian perspective. ( Handa, R, 2004) |
| "We studied 1515 women with postmenopausal osteoporosis under treatment with anti-resorbing agents (alendronate, risedronate, raloxifene) for 13." | 1.35 | Vitamin D status and response to treatment in post-menopausal osteoporosis. ( Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (58.33) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peake, C | 1 |
| Trompeter, A | 1 |
| Liao, EY | 1 |
| Zhang, ZL | 1 |
| Xia, WB | 1 |
| Lin, H | 1 |
| Cheng, Q | 1 |
| Wang, L | 1 |
| Hao, YQ | 1 |
| Chen, DC | 1 |
| Tang, H | 1 |
| Peng, YD | 1 |
| You, L | 1 |
| He, L | 1 |
| Hu, ZH | 1 |
| Song, CL | 1 |
| Wei, F | 1 |
| Wang, J | 1 |
| Zhang, L | 1 |
| Bryson, DJ | 1 |
| Nichols, JS | 1 |
| Ford, AJ | 1 |
| Williams, SC | 1 |
| McLendon, AN | 1 |
| Woodis, CB | 1 |
| Kim, KJ | 1 |
| Min, YK | 1 |
| Koh, JM | 1 |
| Chung, YS | 1 |
| Kim, KM | 1 |
| Byun, DW | 1 |
| Kim, IJ | 1 |
| Kim, M | 1 |
| Kim, SS | 1 |
| Min, KW | 1 |
| Han, KO | 1 |
| Park, HM | 1 |
| Shin, CS | 1 |
| Choi, SH | 1 |
| Park, JS | 1 |
| Chung, DJ | 1 |
| Mok, JO | 1 |
| Baek, HS | 1 |
| Moon, SH | 1 |
| Kim, YS | 1 |
| Lim, SK | 1 |
| Cianferotti, L | 1 |
| Parri, S | 1 |
| Gronchi, G | 1 |
| Rizzuti, C | 1 |
| Fossi, C | 1 |
| Black, DM | 2 |
| Brandi, ML | 1 |
| Adami, S | 1 |
| Giannini, S | 1 |
| Bianchi, G | 2 |
| Sinigaglia, L | 1 |
| Di Munno, O | 1 |
| Fiore, CE | 1 |
| Minisola, S | 1 |
| Rossini, M | 1 |
| Antoniucci, DM | 1 |
| Vittinghoff, E | 1 |
| Palermo, L | 1 |
| Sellmeyer, DE | 1 |
| Benhalima, K | 1 |
| Katrien, B | 1 |
| Mertens, A | 1 |
| Ann, M | 1 |
| Van den Bruel, A | 1 |
| Annick, Vd | 1 |
| Laga, K | 1 |
| Katrien, L | 1 |
| Vanderschueren, D | 1 |
| Dirk, V | 1 |
| Samson, I | 1 |
| Ignace, S | 1 |
| Van Damme, B | 1 |
| Boudewijin, VD | 1 |
| Bouillon, R | 1 |
| Roger, B | 1 |
| Resnick, J | 1 |
| Gupta, N | 1 |
| Wagner, J | 1 |
| Costa, G | 1 |
| Cruz, RJ | 1 |
| Martin, L | 1 |
| Koritsky, DA | 1 |
| Perera, S | 1 |
| Matarese, L | 1 |
| Eid, K | 1 |
| Schuster, B | 1 |
| Roberts, M | 1 |
| Greenspan, S | 1 |
| Abu-Elmagd, K | 1 |
| Ralston, SH | 1 |
| Binkley, N | 1 |
| Boonen, S | 1 |
| Kiel, DP | 1 |
| Reginster, JY | 1 |
| Roux, C | 1 |
| Chen, L | 1 |
| Rosenberg, E | 1 |
| Santora, A | 1 |
| Jain, SK | 1 |
| Roy, SP | 1 |
| Nagi, ON | 1 |
| Turner, C | 1 |
| Dalton, N | 1 |
| Inaoui, R | 1 |
| Fogelman, I | 1 |
| Fraser, WD | 1 |
| Hampson, G | 1 |
| Fuller, KE | 1 |
| Chan, AS | 1 |
| Handa, R | 1 |
| Hamdy, RC | 1 |
| Chesnut, CH | 1 |
| Gass, ML | 1 |
| Holick, MF | 1 |
| Leib, ES | 1 |
| Lewiecki, ME | 1 |
| Maricic, M | 1 |
| Watts, NB | 1 |
| McKinney, J | 1 |
| Muldowney, FP | 1 |
| Sato, Y | 1 |
| Iwamoto, J | 1 |
| Kanoko, T | 1 |
| Satoh, K | 1 |
| Wong, P | 1 |
| Anpalahan, M | 1 |
| Epstein, S | 1 |
| Barone, A | 1 |
| Giusti, A | 1 |
| Pioli, G | 1 |
| Girasole, G | 1 |
| Razzano, M | 1 |
| Pizzonia, M | 1 |
| Palummeri, E | 1 |
| Geller, JL | 1 |
| Hu, B | 1 |
| Reed, S | 1 |
| Mirocha, J | 1 |
| Adams, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women[NCT00729651] | Phase 4 | 343 participants (Actual) | Interventional | 2008-03-20 | Completed | ||
| Quantifying Fatigue of the Respiratory and Swallowing Musculature in Patients With Amyotrophic Lateral Sclerosis[NCT04468191] | 0 participants (Actual) | Interventional | 2021-02-10 | Withdrawn (stopped due to COVID-19 pandemic restrictions for data collection) | |||
| A Phase III (Phase V Program), Open-Label, Randomized, Referred-Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK -0217A/Alendronate Sodium-70 mg/Vitamin D3 5600 I.U. Combination Tablet on Vitamin D Inadequacy in the Treatment of O[NCT00692913] | Phase 3 | 515 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00729651)
Timeframe: 16 weeks
| Intervention | ng/ml (Mean) |
|---|---|
| Fosamax Plus D | 30.08 |
| Fosamax | 17.14 |
(NCT00729651)
Timeframe: Baseline and 16 weeks
| Intervention | Percentage Change Serum PTH (Least Squares Mean) |
|---|---|
| Fosamax Plus D | 8.17 |
| Fosamax | 29.98 |
(NCT00729651)
Timeframe: 16 weeks
| Intervention | participants (Number) | |
|---|---|---|
| With Vitamin D Deficiency | Without Vitamin D Deficiency | |
| Fosamax | 55 | 77 |
| Fosamax Plus D | 2 | 134 |
(NCT00729651)
Timeframe: 16 weeks
| Intervention | participants (Number) | |
|---|---|---|
| With 25 OHD < 20ng/ml at 16 weeks of treatment | With 25 OHD >= 20ng/ml at 16 weeks of treatment | |
| Fosamax | 93 | 39 |
| Fosamax Plus D | 7 | 129 |
"Number of falls per participant was measured.~The fall event rate during the study period was defined as the number of adjudicated falls during the study period divided by the total patient-years in the study. Each participant was to be in the study for approximately one year.~In order to guide and standardize all procedures during the fall adjudication process, a Standard Operating Procedure for Fall Adjudication was created by the~SPONSOR and served as a guideline to standardize operational procedures for fall adjudication." (NCT00692913)
Timeframe: Up to Week 52
| Intervention | Number of Falls (Mean) |
|---|---|
| FOSAVANCE 5600 | 0.51 |
| Referred-Care | 0.45 |
Bone-Specific Alkaline Phosphatase (BSAP) is a serum biochemical marker of bone formation and measured in micrograms/Liter (mcg/L). The percent change was calculated as: [100 * ((Week 26/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy. (NCT00692913)
Timeframe: Baseline and Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| FOSAVANCE 5600 | -46.67 |
| Referred-Care | -39.60 |
N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio (NTx) is a urine biochemical marker of bone resorption and measured in nanomoles (nmol) Bone Collagen Equivalents (BCE)/millimoles (mmol) creatinine. The percent change was calculated as: [100 * ((Week 26/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy. (NCT00692913)
Timeframe: Baseline and Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| FOSAVANCE 5600 | -57.06 |
| Referred-Care | -47.36 |
BSAP is a serum biochemical marker of bone formation and measured in micrograms/Liter (mcg/L). The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy. (NCT00692913)
Timeframe: Baseline and Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| FOSAVANCE 5600 | -51.21 |
| Referred-Care | -43.13 |
NTx is a urine biochemical marker of bone resorption and measured in nanomoles (nmol) Bone Collagen Equivalents (BCE)/millimoles (mmol) creatinine. The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent decrease from baseline, the greater the response to therapy. (NCT00692913)
Timeframe: Baseline and Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| FOSAVANCE 5600 | -58.42 |
| Referred-Care | -50.07 |
"Percentage of participants with serum levels of 25-hydroxyvitamin D below~20 nanograms/milliliter (ng/mL) after 26 weeks of treatment with FOSAVANCE 5600 once weekly versus Referred-Care in postmenopausal women with osteoporosis and at increased risk of falls." (NCT00692913)
Timeframe: Week 26
| Intervention | Percentage of Participants (Number) |
|---|---|
| FOSAVANCE 5600 | 8.6 |
| Referred-Care | 31.0 |
"Percentage of participants with serum levels of 25-hydroxyvitamin D below~20 ng/mL after 52 weeks of treatment (6 month extension study) with FOSAVANCE 5600 once weekly versus Referred-Care in postmenopausal women with osteoporosis and at increased risk of falls." (NCT00692913)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| FOSAVANCE 5600 | 11.3 |
| Referred-Care | 36.9 |
Bone Mineral Density (BMD) as measured by Dual Energy X-Ray Absorptiometry (DEXA) and measured in g/cm^2 was obtained at baseline (visit 1) and Week 52 (visit 13) or at early study discontinuation visit. The percent change was calculated as: [100 * ((Week 52/Baseline)-1)]. The greater the percent change from baseline, the greater the response to therapy. (NCT00692913)
Timeframe: Baseline and Week 52
| Intervention | Percent Change (Least Squares Mean) | |
|---|---|---|
| Lumbar Spine (n= 226/ n=219) | Total Hip (n=227/ n=218) | |
| FOSAVANCE 5600 | 4.92 | 2.22 |
| Referred-Care | 3.91 | 1.40 |
3 reviews available for alendronate and Deficiency, Vitamin D
| Article | Year |
|---|---|
A review of osteoporosis management in younger premenopausal women.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Female; | 2014 |
Management of osteoporosis: the Indian perspective.
Topics: Age Factors; Alendronate; Bone Density; Calcium, Dietary; Female; Humans; India; Life Style; Male; N | 2004 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Die | 2005 |
6 trials available for alendronate and Deficiency, Vitamin D
| Article | Year |
|---|---|
Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Ca | 2018 |
Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial.
Topics: Adult; Aged; Alendronate; Cholecalciferol; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal | 2014 |
Vitamin D insufficiency does not affect response of bone mineral density to alendronate.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; | 2009 |
Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density; Bone Density Conse | 2011 |
Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alendronate; Amino Acids; Bone Density; Bone Resorption; Calcium; Drug Ther | 2006 |
Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitrio | 2007 |
15 other studies available for alendronate and Deficiency, Vitamin D
| Article | Year |
|---|---|
Low-energy atypical femoral shaft and ipsilateral neck fracture: a rare association.
Topics: Aftercare; Aged; Alendronate; Bone Density Conservation Agents; Bone Plates; Bone Screws; Denosumab; | 2017 |
The incidence of vitamin D deficiency amongst patients with a femoral neck fracture: are current bone protection guidelines sufficient ?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Fe | 2013 |
Changing patterns of prescription in vitamin D supplementation in adults: analysis of a regional dataset.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Data | 2015 |
Vitamin D status and response to treatment in post-menopausal osteoporosis.
Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation A | 2009 |
A brown tumor after biliopancreatic diversion for severe obesity.
Topics: Alendronate; Biliopancreatic Diversion; Bone Density; Calcifediol; Calcium; Female; Humans; Hyperpar | 2009 |
Skeletal integrity and visceral transplantation.
Topics: Adult; Alendronate; Biomarkers; Bone Density; Female; Fractures, Bone; Humans; Hyperparathyroidism, | 2010 |
Alendronate induced femur fracture complicated with secondary hyperparathyroidism.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Humans; Hyperparathy | 2011 |
Effect of a 300 000-IU loading dose of ergocalciferol (Vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Ergocalciferols; Female; Fibrobla | 2013 |
Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.
Topics: Alendronate; Bone Remodeling; Drug Therapy, Combination; Female; Humans; Osteoporosis, Postmenopausa | 2004 |
Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Topics: Aged; Alendronate; Bone Density; Female; Humans; Osteoporosis, Postmenopausal; Vitamin D; Vitamin D | 2004 |
The patient's page. Bone health facts.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Dietary Sup | 2005 |
Alendronate and parathyroid hormone.
Topics: Alendronate; Bone Remodeling; Drug Therapy, Combination; Female; Humans; Osteoporosis, Postmenopausa | 2005 |
Osteoporotic fractures and vitamin D deficiency.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractur | 2006 |
The problem of low levels of vitamin D and osteoporosis: use of combination therapy with alendronic acid and colecalciferol (vitamin D3).
Topics: Alendronate; Bone and Bones; Bone Density Conservation Agents; Calcium; Cholecalciferol; Drug Combin | 2006 |
Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Cons | 2008 |